CJC-1295
10 mg (lyophilized)
CAS #:
446036-97-1
LOT #:
261041
Purity:
99.96%
Endotoxin:
PASS
Cap colour is for illustration purposes only
CJC-1295
10 mg (lyophilized)
+ $25 flat-rate shipping · free at $300+ · Interac e-Transfer ·
Volume pricing
Orders with confirmed payment before 2 PM EST on business days ship same day
About this compound
CJC-1295 (Modified GRF 1-29) is a synthetic 29-amino acid analogue of growth hormone-releasing hormone (GHRH) without a Drug Affinity Complex (DAC) modification. Unlike the DAC version, CJC-1295 (no DAC) retains a pharmacokinetic profile closer to endogenous GHRH, producing discrete, pulsatile GH release patterns that more closely mimic physiological secretion. It has been studied in preclinical research for its effects on GH and IGF-1 axis stimulation, body composition, and tissue repair in animal models. The absence of DAC results in a shorter half-life compared to CJC-1295 DAC, making it a distinct research tool compound for investigating pulsatile versus continuous GHRH receptor agonism.
Storage and handling
Store at -20°C lyophilized, away from moisture and UV light. Keep vials sealed until use. Stable for 2+ years in a non-frost-free freezer.
Preclinical research references
Provided for informational context only. All cited studies involve preclinical or in vitro models. Results do not predict human safety or efficacy. These references do not constitute medical claims.
- Rodent models demonstrated that CJC-1295 (no DAC) administration produced significant acute elevations in circulating GH and downstream IGF-1 levels, with a pulsatile release pattern consistent with physiological GHRH stimulation of the pituitary somatotrophs (Jetté et al., 2005)
- Animal body composition studies observed improvements in lean mass accrual and reductions in adipose tissue mass following repeated administration of short-acting GHRH analogues structurally related to CJC-1295, consistent with GH-mediated anabolic and lipolytic signaling (Frohman et al., 1992)
- Rat pituitary assay models showed dose-dependent activation of GHRH receptor-coupled adenylate cyclase pathways and stimulation of GH secretory granule exocytosis following administration of Modified GRF 1-29 analogues, confirming receptor specificity and functional pituitary responsiveness (Bowers et al., 1998)
Shipping & returns
1–5 business days (5–7 for BC, NL and remote areas), Canada-wide tracked courier, double tamper-proof packaging.
All sales final. Damaged or incorrect orders must be reported within 24 hours with photos.
Every batch independently tested for purity. COA on file and available before purchase.
FAQ — CJC-1295
For research use only. Not for human or veterinary administration.